241 results on '"Taieb V"'
Search Results
2. CO88 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis
3. PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year
4. EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
5. CO10 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Psoriatic Arthritis
6. Résolution des enthésites et des arthrites périphériques avec le bimékizumab chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et BE MOBILE 2
7. CO49 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Ixekizumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis
8. Le bimékizumab permet le maintien des réponses cliniques évaluées par des critères stricts jusqu’à la semaine 52 chez les patients atteints de spondyloarthrite axiale : résultats des études de phase III BE MOBILE 1 et BE MOBILE 2
9. Maintien de l’efficacité du bimékizumab pendant 52 semaines chez les patients atteints de rhumatisme psoriasique, naïfs de biologique et répondeurs à la semaine 16 : résultats de BE OPTIMAL, étude de phase III avec un bras de référence actif
10. POS1533 BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
11. POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
12. AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
13. POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
14. AB1100 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY
15. POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
16. PCR117 Achieving Stringent Clinical Disease Control Criteria Is Associated With Improved Quality of Life Measures in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Randomised, Placebo-Controlled Studies
17. PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies
18. L’atteinte de critères cliniques plus stricts est associée à de plus importantes améliorations des critères patients (fonction physique, douleur) chez les patients atteints de rhumatisme psoriasique actif : résultats à 16 semaines de 2 études de phase III
19. Le bimékizumab améliore les principaux symptômes rapportés par les patients atteints de spondylarthrite axiale, notamment les douleurs rachidiennes et la fatigue : résultats de deux études de phase III
20. Le bimékizumab améliore la fonction physique et la qualité de vie liée à l’état de santé chez les patients atteints de spondyloarthrite axiale : résultats de deux études de phase III
21. POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
22. MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
23. Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies
24. Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis
25. PBI3 Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis
26. SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis
27. SA50 Comparative Efficacy of Bimekizumab in Biologic/Targeted Synthetic DMARD-Naïve Patients with Axial Spondyloarthritis: Results from a Systematic Literature Review and Network Meta-Analysis
28. SA2 A Systematic Literature Review and Meta-Analysis of Work Productivity in Patients with Axial Spondyloarthritis Treated with Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
29. RWD136 Real-World Use of Biologic Disease-Modifying Anti-Rheumatic Drugs in US Patients with Ankylosing Spondylitis: Persistence, Factors Associated with Discontinuation, and Dosing Patterns
30. PCR65 Psychometric Assessment of the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from the Phase 3 BE OPTIMAL and BE COMPLETE Trials of Bimekizumab in Patients with Psoriatic Arthritis
31. PCR68 Association of Clinical Response Criteria and Disease Activity Levels with Physical Function and HRQoL in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
32. PRO141 Treatment Patterns PRIOR to the Use of Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia in Germany
33. PNS372 A SIMULATION STUDY COMPARING THE PERFORMANCE OF DISCRETE CHOICE EXPERIMENT AND SWING WEIGHTING FOR ELICITATION OF PREFERENCES
34. PNS319 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS
35. PBI64 CHARACTERISTICS OF CLINICAL TRIALS DESIGNED TO ASSESS GENE THERAPIES
36. PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES
37. PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS
38. PNS343 THE COMPLETENESS OF CLINICALTRIALS.GOV. - WHAT IS THE RATE OF PUBLISHED CLINICAL TRIALS REGISTERED ON THE WEBSITE?
39. PBI76 EVOLUTION OF INTERVENTIONAL TRIALS FOR GENE THERAPIES
40. PRO54 ECONOMIC BURDEN OF CARE AND TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: TWO SYSTEMATIC LITERATURE REVIEWS
41. PIN4 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN OTHERWISE HEALTHY AND HIGH-RISK ADULTS
42. Economic burden of care and treatment options for patients with Rett syndrome: Two systematic literature reviews
43. PCV104 PSYCHOMETRIC VALIDATION OF THE ‘GOOD DAY BAD DAY’ ITEM IN A NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH) POPULATION
44. PRO35 ECONOMIC BURDEN OF CARE IMPOSED ON PATIENTS WITH RETT SYNDROME: A SYSTEMATIC LITERATURE REVIEW
45. PRO1 TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: A SYSTEMATIC LITERATURE REVIEW
46. PIN7 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN HIGH-RISK PATIENTS
47. PUK36 - COMPARISON OF PATIENT-REPORTED OUTCOMES IN RANDOMIZED CONTROLLED TRIALS AND IN OBSERVATIONAL STUDIES FOR OVERACTIVE BLADDER: A SYSTEMATIC LITERATURE REVIEW
48. PIN8 - COMPARATIVE EFFICACY OF FIDAXOMICIN, VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION: A NETWORK META-ANALYSIS
49. PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS: A SYSTEMATIC LITERATURE REVIEW
50. PRM181 - USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE FOR A SYSTEMATIC LITERATURE REVIEW OF UTILITIES IN INFECTIOUS DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.